Pure Biologics

Pure Biologics EBITDA Growth YoY

The Year-over-Year EBITDA Growth of Pure Biologics (PUR.WA) as of Nov 17, 2026 is 47.57 %. In the previous year, Year-over-Year EBITDA Growth was 53.44 % — a change of -11.00% (lower).

EBITDA Growth YoY

47.57 %

YoY

-11.00%

Last updated:

Year-over-Year EBITDA Growth of Pure Biologics is 2025 47.57 % . Year-over-Year EBITDA Growth of Pure Biologics was 2024 53.44 % . It decreases by -11.00% lower compared to the previous year.

The Pure Biologics EBITDA Growth YoY history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Growth YoY
Date
EBITDA Growth YoY
Jan 1, 2018
-49.08 PLN
Jan 1, 2019
-764.77 PLN
Jan 1, 2020
-217.93 PLN
Jan 1, 2021
34.56 PLN
Jan 1, 2022
-192.67 PLN
Jan 1, 2023
-17.18 PLN
Jan 1, 2024
53.44 PLN
Jan 1, 2025
47.57 PLN
The Pure Biologics EBITDA Growth YoY history
YEAREBITDA Growth YoYYoY
47.57 %-11.00%
53.44 %-411.10%
-17.18 %-91.08%
-192.67 %-657.47%
34.56 %-115.86%
-217.93 %-71.50%
-764.77 %+1,458.31%
-49.08 %-304.89%
23.95 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Pure Biologics Stock analysis

What does Pure Biologics do? Pure Biologics SA, headquartered in Wrocław, Poland, operates in the Health Care sector as a biotechnology company. It focuses on research and development of innovative biological medicines and medical devices for therapeutic and diagnostic applications. The company employs 53 full-time staff and was listed on the stock market on 11 December 2018. Founded in August 2010, it remains based in Wrocław, focusing on biopharmaceutical solutions. Pure Biologics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pure Biologics stock

Year-over-Year EBITDA Growth of Pure Biologics is 47.57 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year EBITDA Growth Pure Biologics since 2006 – with annual values, charts, and detailed analysis.

EBITDA growth measures the percentage change in EBITDA compared to the prior year. It shows changes in operating cash earnings before capital structure effects.

To evaluate Year-over-Year EBITDA Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBITDA Growth.

Year-over-Year EBITDA Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBITDA Growth's Pure Biologics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Pure Biologics

All Key Metrics — Pure Biologics